Blister pack with dollars instead of pills From 2011-2019, large drug companies had a return on investment capital of 17.3 percent, compared to the average ROIC across all other industries of 11.5 percent. (Photo: Shutterstock)

Pharma has been countering the call for government-mandated price restrictions by arguing that lower industry revenues would stymie development of needed drugs.

A group of researchers at the West Health Policy Center and Johns Hopkins Bloomberg School of Public Health say that’s a lot of hooey–claiming they have the data to back that up.

Complete your profile to continue reading and get FREE access to, part of your ALM digital membership.

Your access to unlimited content isn’t changing.
Once you are an ALM digital member, you’ll receive:

  • Critical information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and events.
  • Access to other award-winning ALM websites including and

Already have an account?

Katie Kuehner-Hebert

Katie Kuehner-Hebert is a freelance writer based in Running Springs, Calif. She has more than three decades of journalism experience, with particular expertise in employee benefits and other human resource topics.

More from this author



Join BenefitsPRO

Don’t miss crucial news and insights you need to navigate the shifting employee benefits industry. Join now!

  • Unlimited access to - your roadmap to thriving in a disrupted environment
  • Access to other award-winning ALM websites including and
  • Exclusive discounts on and ALM events.

Already have an account? Sign In Now
Join BenefitsPRO

Copyright © 2023 ALM Global, LLC. All Rights Reserved.